Novo Nordisk's successful GLP-1 drug is creating new opportunities for the Danish pharmaceutical giant, which has stated it can no longer rely exclusively on drugs developed in-house, Danish financial daily Børsen reports.
In an interview with Endpoints News, CEO Lars Fruergaard Jørgensen says that Novo Nordisk will continue to make investments over the next year.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.